Home›People›Kush Parmar
KP

Kush Parmar

10% owner at Skye Bioscience. Also a director at Ensoma.

ExecutiveDirectorPublic company
Updated Nov 9, 2026·Latest SEC filing Sep 24, 2026·Suggest an edit

About Kush Parmar

Kush Parmar is a 10% owner at Skye Bioscience.

Form D filings name Kush Parmar as a director at Ensoma.

Kush Parmar reports to the SEC as a director, officer or major shareholder of 18 public companies, including Latigo Biotherapeutics (LTGO), Entrada Therapeutics (TRDA) and Camp4 Therapeutics (CAMP).

Kush Parmar first appears on SEC filings in 2016.

Experience

This experience comes from SEC filings. The years are when the filings name Kush Parmar in the role, so the role may have started earlier or lasted longer.

Skye Bioscience, Inc.
10% owner
2023 – 2026 · Public company (SKYE)
Latigo Biotherapeutics, Inc.
10% owner
2026 · Public company (LTGO)
Entrada Therapeutics, Inc.
Director and 10% owner
2021 – 2026 · Public company (TRDA)
Camp4 Therapeutics Corp
10% owner
2024 – 2026 · Public company (CAMP)
Artiva Biotherapeutics, Inc.
10% owner
2024 · Public company (ARTV)
Rallybio Corp
Director and 10% owner
2021 – 2024 · Public company (RLYB)
Enliven Therapeutics, Inc.
10% owner
2023 – 2024 · Public company (ELVN)
Ensoma, Inc.
Director
2021 – 2023 · Boston, MA
CinCor Pharma, Inc.
10% owner
2022 – 2023 · Public company (CINC)
Akouos, Inc.
Director and 10% owner
2020 – 2022 · Public company (AKUS)
Q32 Bio Inc.
Director and 10% owner
2018 – 2022 · Public company (QTTB)
Vor Biopharma Inc.
Director and 10% owner
2021 – 2022 · Public company (VOR)
Cabaletta Bio, Inc.
10% owner
2019 – 2021 · Public company (CABA)
IPI Legacy Liquidation Co
10% owner
2021 · Public company (IMPLQ)
5:01 Acquisition Corp.
Co-CEO and director
2020 · Public company (FVAM)
Aprea Therapeutics, Inc.
10% owner
2019 – 2020 · Public company (APRE)
Arvinas, Inc.
Director
2018 – 2019 · Public company (ARVN)
scPharmaceuticals Inc.
Director
2017 – 2018 · Public company (SCPH)
Audentes Therapeutics, Inc.
Director
2016 – 2018 · Public company (BOLD)

Key Colleagues at Startups

The people Kush Parmar works with at each company, as listed on that company's latest Form D.

Ensoma, Inc. · Form D/A, May 23, 2023
NS
Nihal Sinha
Director
EN
Emile Nuwaysir
Executive officer and director
KH
MC
Mark Chin
Director
AS

Sources

  1. SECEnsoma, Inc. Form D/A, filed May 23, 2023
  2. SECForms 3, 4 and 5 filed by Kush Parmar (SEC filer 1664281)